Refuge applies CAR T engineering platform to TILs through MD Anderson deal

Refuge is taking a first step in applying its synthetic biology-based cell engineering technology beyond CAR T cells through a deal with MD Anderson.

Refuge Biotechnologies Inc. will provide the University of Texas MD Anderson Cancer Center exclusive rights to its cell engineering technology for tumor infiltrating lymphocytes (TILs), another type of T cell therapy for cancer that uses the endogenous TCR rather than a CAR to target cancer cells...